Jianfeng Xie
13
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury
Role: lead
Influenza A-associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit in China
Role: lead
Epidemiological Investigation of Central Venous Catheter-related Bloodstream Infections in Icus in China
Role: lead
The Effect and Mechanism of lncRNA NBR2 Regulating Endothelial Pyroptosis by Targeting GSDMD in Sepsis
Role: lead
Long-term Quality of Life Among Survivors of Sepsis in China Assessed by EQ-5D
Role: lead
Shenfu Injection Improves Arterial Vascular Reactivity
Role: lead
Dynamic Alterations of Th2/Th1 With New Onset of Community-acquired Severe Sepsis Patients
Role: lead
Effects of Different Driving Pressure on Lung Stress, Strain and Mechanical Power in Patients With Moderate to Severe ARDS
Role: lead
ARDS Prediction Score in Critically Ill Patients in China
Role: lead
Epidemiology of Sepsis in China
Role: lead
The Classification of Difficult Weaning and the Predictive Value of Relative Factors for Difficult Weaning
Role: lead
Antimicrobial Stewardship Reduces MDRO Isolates in Critically Ill Patients
Role: lead
Diagnostic and Prognostic Value of Combination Biomarkers in the Critically Ill Patient With Sepsis.
Role: lead
All 13 trials loaded